NEW YORK, May 6 (GenomeWeb News) - Correlogic Systems, the Uniformed Services University of the Health Sciences, and the Henry M. Jackson Foundation for the Advancement of Military Medicine intend to co-develop a blood test for the detection of prostate cancer based on the company's protein pattern-recognition approach, the firm said today.
Two concurrent studies will involve up to 2,000 men with prostate cancer. The first study will use Correlogic's ProteomeDx pattern recognition technology to try to develop a blood test for prostate cancer detection that is more effective t
With the current PSA test, approximately 75 percent of men who test positive end up undergoing unnecessary prostate biopsies, according to Correlogic.
In the second study, researchers will try to use the technology to try to develop a test to distinguish between indolent and aggressive prostate cancer.